PhoreMost

Updated November 2023.

Employees say this is a great place to work*

Company Overview

About PhoreMost

PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary 'Protein Interference' (PROTEINi®) technology, SITESEEKER® systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context. Using this platform, PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of unmet diseases.

Company Size 50 UK-based Employees
(Medium)

INDUSTRY BioPharma

CONNECT

PhoreMost Head Office

East England, United Kingdom

Employee Demographics

Tenure

<2 years - 62%
2-5 years - 28%
6-10 years - 10%

Company Culture at PhoreMost

The employee experience below at PhoreMost, compared to a typical company.

95% of employees at PhoreMost say it is a great place to work*, compared to 54% of employees at a typical UK based company.

PhoreMost

95%

Typical Company

54%

*Responses to the statement “Taking everything into account, I would say this is a great place to work.” Source: Great Place To Work® 2021 Global Employee Engagement Study.